| Research PurposesBy observing changes in tumor immune five, gastrointestinal symptoms, quality of life scale, liver and kidney function in patients with mild moxibustion before and after chemotherapy, and to explore the impact of gastrointestinal toxicity and quality of life in mild moxibustion theraPy on immune function, as Ai moxibustion to reduce the toxicity of chemotherapy provide clinical basis.Research MethodsPatient cases were from Jiangsu Provincial Hospital oncology ward of chemotherapy, the61Patients met the inclusion criteria of the test cases, using the method of random lists, divided into treatment (mild moxibustion plus chemotherapy) and a control group of31cases (chemotherapy) grouP30cases. Both groups were the same chemotherapy and western medicine treatment of chemotherapy side effects.Treatment groups:mild moxibustion+conventional chemotheraPy.Acupoints:the main point:God Que, full three years. points:Gynecologic Oncology with Sanyinjiao; gastrointestinal symptoms with severe abdominal; Qi with the sea air; blood stasis with a sea of blood.OPeration:After the patient supine or sitting position, accurately selected points, the healer will end alignment ignited moxa patient’s skin surface points from2-3cm, moxibustion to patients with localized skin feeling warm and comfortable, flushing for the degree;6times a week per hole15min.Control group:only chemotherapy, not moxibustion.Observation Period:Two groups were from the first day after chemotherapy before one day to the next chemotherapy treatment for the1, about20days of observation of three courses. Before treatment1,2,3third course of treatment effect assessed seParately, a total of4times the effect assessment. Observed immune five (IgG, IgA, IgM, complement C3, complement C4), gastrointestinal toxicity (nausea, vomiting, loss of appetite, diarrhea, constipation), quality of life scale and liver and kidney function (AST, ALT, urea creatinine) before and after treatment. The clinical research data using the data sheet SPSS19.0statistical software for statistical analysis of the distribution of cancer types, KPS score, gender ratio, gastrointestinal symptoms of scores using the chi-square test; immune five, liver and kidney function and quality of life scale Rating count data such as mean±standard deviation between groups were compared using independent sample t test completely, paired t test comparison within groups, heterogeneity of variance using non-parametric tests.Results1Mild moxibustion effects on immune functionTreatment group before and after treatment:five were significantly increasedcompared with pre-immune therapy, with a very significant difference (P<0.01).The control group before and after treatment:After five indicators decreased immune theraPy, statistically significant (P<0.05), and IgM, complement C3, C4complement a significant difference (P<0.01).Both groups before and after treatment:no treatment comparison between the two groups before immunization five groups statistically significant (P>0.05), comParable; immune targets after the first five courses of treatment group increased slightly in the control group were down, but no statistical significance between the two groups (P>0.05), second course, after the third course of treatment group gradually increased, while the control grouP decreased, gradually significant differences (P<0.05, P<0.01).2Mild moxibustion effect on gastrointestinal symptomsBefore and after the treatment group comparison:After treatment, loss of appetite symptoms, but not statistically significant (P>0.05); nausea, vomiting symptoms, there was a significant statistical significance (P<0.01); diarrhea, constipation symptoms improved slightly, No statistically significant (P>0.05).The control group before and after treatment:After treatment, loss of appetite, nausea, vomiting and other symptoms worse, there was a significant statistical significance (P<0.01); diarrhea, constipation symPtoms increased significantly, with statistical significance (P<0.05).Both groups before and after treatment:comparison between two groups before treatment group, loss of appetite, nausea, vomiting, diarrhea, constipation and other symptoms no significant difference between comparable (P>0.05). After the first and second course of treatment, the two groups have different levels of gastrointestinal symptoms increase, but the treatment group than in control group, no significant difference (P>0.05); After the first three courses, with a statistically significant difference (P<0.05).3Mild moxibustion impact on quality of lifeTreatment group before and after treatment:functional scores decreased significantly after treatment dysfunction, symptom scores significantly increased symptoms, decreased quality of life, with a very significant statistical significance (P<0.01).The control group before and after treatment:functional scores decreased significantly after treatment dysfunction, symptom scores also increased significantly symptoms, decreased quality of life, with a very statistically significant (P<0.01).Both groups before and after treatment:comparison between two groups before treatment function, symptom score was no significant difference, comparable (P>0.05). After treatment function scores decreased in the treatment group than the control group decreased extent, after the third treatment, the treatment group was significantly lower than the degree of functional decline in the control grouP, with a very significant difference (P<0.01); symptom score after treatment are rising, the treatment group than the control group to increase the degree of symptoms, beginning from the second course of treatment, the treatment group symptom score was significantly lower than the control group (P<0.01), illustrate the effect of the treatment group than the control group.4Mild moxibustion effects on liver and kidney function:Treatment group before and after treatment:After treatment of urea, creatinine decreased slightly, there was no statistically significant difference (P>0.05); aspartate aminotransferase (AST), alanine aminotransferase (ALT) are rising, AST increased by a very significant difference (P<0.01), ALT was no significant difference (P>0.05). The control group before and after treatment:after treatment increased urea, creatinine, AST, ALT varying degrees, in addition to urea, creatinine before treatment were significantly different than the (P<0.05), AST, ALT had significant statistical significance (P<0.01).Both groups before and after treatment:before treatment, between the two groups of urea, creatinine, AST, ALT groups were not statistically significant (P>0.05), comparable. After the first and second course of treatment, the treatment group urea, creatinine decreased slightly in the control group of urea, creatinine, there are different degrees of increase, but the two groups showed no significant difference (P>0.05); grouPs AST, ALT varying degrees the increase in the treatment group than the control group, although the degree of increase, but there is no statistical significance (P>0.05); after the third treatment, the treatment group of urea, creatinine, although lower than the control group, but no statistical significance (P>0.05), the treatment group AST, ALT were obviously less than the control group (P<0.01), prove that moxibustion can reduce chemotherapy on liver and kidney function damage.Conclusion1Mild moxibustion can reduce the effects of chemotherapy on the immune suppression.2Mild moxibustion can significantly improve the toxicity of chemotherapy on the digestive tract.3Mild moxibustion can reduce the toxicity of chemotherapy and improve the quality of life.4. Mild moxibustion can reduce chemotherapy on liver and kidney function damage. |
PDF Full Text Request